|
Q3 FY2026
As of Sep 30, 2026
|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||
| Current assets: | ||||||||||||||||
| Cash and cash equivalents | ||||||||||||||||
| Collaboration receivable | ||||||||||||||||
| Prepaids and other current assets | ||||||||||||||||
| Total current assets | ||||||||||||||||
| Fixed assets, net | ||||||||||||||||
| Other assets | ||||||||||||||||
| Total assets | ||||||||||||||||
| Liabilities and Stockholders' Equity | ||||||||||||||||
| Current liabilities: | ||||||||||||||||
| Accounts payable | ||||||||||||||||
| Accrued expenses | ||||||||||||||||
| Deferred collaboration revenue | ||||||||||||||||
| Total current liabilities | ||||||||||||||||
| Total liabilities | ||||||||||||||||
| Stockholders' equity: | ||||||||||||||||
| Common stock, $0.0001 par value; 200,000,000 shares authorized; 23,457,849 and 20,934,456 shares issued and outstanding as of September 30, 2026 or December 31, 2025, respectively | ||||||||||||||||
| Additional paid-in capital | ||||||||||||||||
| Subscription receivable | ||||||||||||||||
| Accumulated deficit | ||||||||||||||||
| Total stockholders' equity | ||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||
Loading...